Research use only, not for human consumption. Email [email protected]
← Research status explorer
Rebuild / Repair & longevity

Thymosin Beta-4 (TB-4)

Also known as: TB-500, Tβ4, Thymosin Beta 4

Current research status Phase 2
Human clinical research
Preclinical
Phase 1
Phase 2
Phase 3
Approved Molecule*

What is it?

Thymosin beta-4 (Tβ4) is a 43-amino-acid peptide found in most human cells and first identified as an actin-binding (G-actin sequestering) peptide. It has been studied in laboratory and clinical research for its reported roles in cell migration, tissue repair, blood-vessel formation and inflammation, with human work concentrated on eye-surface conditions, chronic skin ulcers and early-phase cardiac programmes. The name "TB-500" is used commercially for products that are not necessarily the same molecule as full-length Tβ4, so evidence for full-length Tβ4 should not be assumed to apply to them.

Research overview

This entry describes research on full-length Thymosin Beta-4 (Tβ4), the natural 43-amino-acid peptide — not a claim about any specific shorter fragment sometimes marketed under the name "TB-500." Full-length Tβ4 has progressed from preclinical research into human clinical investigation, with Phase 2 studies evaluating Tβ4 formulations in areas including ocular-surface disease and chronic wound healing. A 72-participant Phase II dry-eye trial did not meet its prespecified primary endpoints, though several secondary measures showed statistically significant improvement — a useful reminder that reaching Phase 2 is not the same as proving efficacy.

Mechanism of action

Tβ4 is best known as a G-actin sequestering peptide: it is described as binding monomeric actin in a 1:1 ratio, which helps set the pool of unpolymerised actin available for cell movement and shape change [PMID 36464872]. This is the most established property of the peptide, although how much of its reported tissue-repair activity depends on actin binding versus other interactions is still debated.

In mouse cardiac work, Tβ4 was reported to form a complex with PINCH and integrin-linked kinase (ILK), increasing activity of the survival kinase Akt and enhancing early cardiomyocyte survival after coronary ligation [PMID 15565145]. A separate mouse study reported that Tβ4 is needed for coronary vessel development and can stimulate outgrowth and differentiation of adult epicardial cells; the Tβ4 cleavage product N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) was implicated in the pro-angiogenic effect [PMID 17108969]. These are proposed pathways drawn from animal and cell models, not demonstrated mechanisms in people.

In cultured endothelial cells, Tβ4 was reported to act as a chemoattractant, speed closure of a scratch wound and increase matrix metalloproteinase production, and to stimulate cell migration in an implanted-gel assay in vivo [PMID 9194528]. In skin-wound models in diabetic and aged mice, Tβ4 treatment was associated with increased wound contraction and collagen deposition [PMID 12581423]. Whether these effects occur at the exposures reached by any given route of administration in humans is not established.

Adult human evidence

Human data for full-length Tβ4 (as formulations developed for clinical trials, not as products sold under the name TB-500) come mainly from eye-surface studies in adults. A single-centre, double-masked, placebo-controlled Phase II trial of Tβ4 ophthalmic solution (RGN-259) randomised 72 participants with moderate to severe dry eye for 28 days using a controlled adverse environment model. Neither primary endpoint (ocular discomfort or inferior corneal staining at the primary visit) differed significantly between groups, although several secondary endpoints, including discomfort scores in the controlled adverse environment on day 28 and central and superior corneal staining, were reported as favouring Tβ4, and no adverse events were observed [PMID 26056426]. Because the primary endpoints were not met, the secondary findings are hypothesis-generating rather than confirmatory. The registry record for a 72-participant Phase II trial of this solution (NCT01387347) lists participants aged 18 to 85.

A very small multicentre, randomised, double-masked, vehicle-controlled Phase 2 trial in nine adults with severe dry eye (including graft-versus-host disease) reported larger reductions in ocular discomfort and corneal staining at day 56 with RGN-259 than with vehicle, and described the drops as well tolerated [PMID 25826322]. With nine patients (analysed by eye, 12 treated eyes versus 6 control eyes), the result is preliminary and sensitive to chance and to imbalances between groups.

Nine adults (ages 37 to 84) with chronic non-healing neurotrophic corneal epithelial defects were treated with Tβ4 eye drops under compassionate use; six patients with geographic defects were reported to show marked healing, while three with punctate defects showed no demonstrable change, and stromal thinning occurred in one patient [PMID 20536469]. This is an uncontrolled case series and cannot show that the drops caused the healing.

In a double-blind, placebo-controlled, dose-escalation Phase 2 study in 73 patients with venous stasis ulcers across Italian and Polish sites, topical Tβ4 had a safety profile reported as acceptable and comparable to placebo, and the authors suggested that one dose level might accelerate healing, with complete healing in about 25% of patients within 3 months [PMID 20536470]. The abstract does not give participant ages; the registry record for a corresponding trial (NCT00832091, Italy and Poland) lists participants aged 18 to 79. Efficacy statements in this report are exploratory and were not derived from a confirmatory comparison.

Phase I safety studies of recombinant human Tβ4 (NL005) in healthy volunteers (54 participants in the single-dose part and 30 in the multiple-dose part) reported mild to moderate adverse events, no dose-limiting toxicities or serious adverse events, and no obvious accumulation on repeated administration [PMID 34346165]. These studies address tolerability and pharmacokinetics, not efficacy. The abstract does not state participant ages; the corresponding registry records (NCT04555824 and NCT04555850) list ages 18 to 50.

No adult human neurological efficacy data and no adult human efficacy data for any musculoskeletal or tendon use were identified in the records reviewed. Cardiac development programmes exist (see research status), but a peer-reviewed report in which adult age could be confirmed from the record was not used here. No clinical study of products sold as TB-500 was identified in the PubMed searches run for this dossier; one registered trial of a thymosin beta 4 17-23 fragment labelled TB-500 is listed as recruiting (NCT07487363, no results).

Preclinical evidence

Cardiac models. In mice, Tβ4 treatment after coronary artery ligation was reported to upregulate ILK and Akt activity in the heart, enhance early myocyte survival and improve cardiac function, and Tβ4 promoted migration and survival of cardiomyocytes in culture [PMID 15565145]. In a separate mouse study, Tβ4 was reported to be essential for coronary vessel development and to stimulate outgrowth from adult epicardial explants, restoring progenitor-like properties [PMID 17108969]. These findings come from mouse and cell systems; the doses, routes and timing used do not translate directly to humans.

Wound-healing and angiogenesis models. Tβ4, delivered in saline or a hydrogel, was reported to accelerate full-thickness dermal wound repair in db/db diabetic and 26-month-old mice, with increased wound contraction and collagen deposition and, in aged mice, increased keratinocyte migration; a seven-amino-acid synthetic peptide matching the actin-binding region of Tβ4 showed comparable activity in aged animals [PMID 12581423]. In vitro, Tβ4 stimulated directional migration of human umbilical vein endothelial cells four- to sixfold above medium alone, and increased cell migration into subcutaneously implanted Matrigel in vivo [PMID 9194528].

Tendon model using a product labelled TB-500. In a 32-rat Achilles tendon transection-and-repair study, a group given "synthetic thymosin beta-4 (TB-500)" reported a higher maximum load to failure and improved histological scores at four weeks than controls; combining it with BPC-157 conferred no additional benefit. The authors describe the work as exploratory and preliminary [PMID 42542926]. The abstract does not describe the chemical identity of the TB-500 used, so it cannot be assumed to be identical to full-length Tβ4. On naming, a mass-spectrometry study reported identifying the N-terminal acetylated 17-23 fragment of human thymosin beta 4 (Ac-LKKTETQ) in a formulation sold as TB-500 [PMID 22962027], and a veterinary doping-control paper likewise describes TB-500 as a synthetic, N-acetylated LKKTETQ peptide rather than the full 43-amino-acid protein [PMID 23084823]. Both are analytical chemistry papers, not efficacy studies.

Evidence limitations

  • The strongest human data are for topical ophthalmic formulations in specific eye conditions; they cannot be extended to other tissues, routes of administration or uses.
  • Adult human trials are small or early-phase, and in the larger dry-eye Phase II trial the pre-specified primary endpoints were not met; positive secondary findings need confirmation.
  • Most cardiac, angiogenesis, wound and tendon findings come from mice, rats and cultured cells and have not been shown to translate to people.
  • Mechanistic explanations (actin binding, ILK/Akt, epicardial activation, AcSDKP) are proposed from experimental models; their relative contribution is unresolved.
  • "TB-500" has been reported in the analytical literature to contain a synthetic N-acetylated 17-23 fragment (LKKTETQ) of thymosin beta 4 rather than the full 43-amino-acid peptide [PMID 22962027, PMID 23084823], and one trial registry entry specifies the 17-23 fragment, so findings for full-length Tβ4 should not be assumed to carry over. Usage is inconsistent: the rat tendon study calls its TB-500 "synthetic thymosin beta-4" without defining it in the abstract.
  • Long-term safety, immunogenicity and pharmacokinetics of unregulated, non-clinical-grade products are not characterised in the peer-reviewed literature reviewed here.
  • Several Phase 3 programme results (ARISE-1, ARISE-2, ARISE-3, SEER-1) were not found as peer-reviewed publications in PubMed, so their outcomes are not summarised in this dossier.

Research and regulatory status

Clinical development of full-length Tβ4 has been led by sponsors using ophthalmic RGN-259 and topical RGN-137. ClinicalTrials.gov lists completed Phase 2/3 and Phase 3 dry-eye trials (ARISE-1, NCT02597803; ARISE-2, NCT02974907; ARISE-3, NCT03937882), a Phase 3 neurotrophic keratopathy trial terminated for a business decision (SEER-1, NCT02600429), and a second Phase 3 neurotrophic keratopathy trial listed as completed (SEER-2, NCT05555589); results are posted for some of these but were not interpreted here. Registered injectable Tβ4 programmes for acute myocardial infarction include Phase 2 trials by Beijing Northland Biotech (for example NCT05485818 and NCT05984134, both listed as completed) and an earlier US Phase 2 listed as withdrawn (NCT01311518). No approved indication was identified in the records reviewed, and regulatory databases were not searched.

Key studies

Adult human study

Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.

Sosne G, Ousler GW · Clinical ophthalmology (Auckland, N.Z.) · 2015

Design
Single-centre, prospective, double-masked, randomised, placebo-controlled Phase II trial (28 days of treatment)
Participants / model
Adults with moderate to severe dry eye (registry record NCT01387347 lists ages 18-85)
Sample size
72 participants
Principal findings
Neither primary endpoint (ocular discomfort, inferior corneal staining) differed significantly between groups. Several secondary endpoints, including day-28 discomfort in the controlled adverse environment and central and superior corneal staining, were reported as favouring Tβ4, and no adverse events were observed.
Limitations
Primary endpoints were not met, so secondary findings are exploratory. Single centre, short treatment duration, and the abstract does not report participant ages.

PubMed 26056426 DOI 10.2147/OPTH.S80954

Adult human study

Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.

Sosne G, Dunn SP, Kim C · Cornea · 2015

Design
Small multicentre, randomised, double-masked, placebo (vehicle)-controlled Phase 2 trial
Participants / model
Adults with severe dry eye including graft-versus-host disease (NCT01393132 lists ages 18-90)
Sample size
9 patients (12 RGN-259-treated eyes, 6 vehicle eyes)
Principal findings
At day 56 the treated group was reported to have a 35.1% reduction in ocular discomfort and a 59.1% reduction in total corneal fluorescein staining compared with vehicle, with improvements in tear film breakup time and tear volume; the drops were described as safe and well tolerated.
Limitations
Only nine patients, analysed by eye, so results are preliminary and sensitive to chance and baseline imbalance. Short follow-up.

PubMed 25826322 DOI 10.1097/ICO.0000000000000379

Adult human study

Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.

Dunn SP, Heidemann DG, Chow CY, et al. · Annals of the New York Academy of Sciences · 2010

Design
Compassionate-use case series (indexed by PubMed as a review)
Participants / model
Patients aged 37-84 with chronic non-healing neurotrophic corneal epithelial defects
Sample size
9 patients
Principal findings
Six patients with geographic defects were reported to show marked healing without clinically significant neovascularisation, while three with punctate defects had no demonstrable change; all reported reduced ocular irritation after starting treatment, and stromal thinning occurred in one patient.
Limitations
Uncontrolled, very small and non-randomised, so natural healing or other care cannot be excluded as explanations.

PubMed 20536469 DOI 10.1111/j.1749-6632.2010.05471.x

Adult human study

The effect of thymosin treatment of venous ulcers.

Guarnera G, DeRosa A, Camerini R, et al. · Annals of the New York Academy of Sciences · 2010

Design
Multicentre, double-blind, placebo-controlled, dose-escalation Phase 2 randomised study of topical Tβ4
Participants / model
Patients with venous stasis ulcers at eight European sites (five Italy, three Poland); the corresponding registry record NCT00832091 lists ages 18-79
Sample size
73 patients (the registry record lists 72)
Principal findings
The safety profile at all doses was described as acceptable and comparable to placebo. The authors suggested that one dose level may have potential to accelerate wound healing, with complete healing within 3 months in about 25% of patients, especially those with smaller or milder wounds.
Limitations
Phase 2 dose-finding design with exploratory efficacy statements; the abstract gives no confirmatory comparison versus placebo and no participant ages.

PubMed 20536470 DOI 10.1111/j.1749-6632.2010.05490.x

Adult human study

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.

Wang X, Liu L, Qi L, et al. · Journal of cellular and molecular medicine · 2021

Design
Randomised, double-blind, placebo-controlled, single- and multiple-dose Phase I study of recombinant human Tβ4 (NL005)
Participants / model
Healthy volunteers (registry records NCT04555824 and NCT04555850 list ages 18-50)
Sample size
54 healthy subjects in the single-dose part; 30 in the multiple-dose part
Principal findings
Adverse events were mild to moderate; no dose-limiting toxicities or serious adverse events were reported, and exposure increased with dose without obvious accumulation after repeated administration.
Limitations
Safety, tolerability and pharmacokinetic study in healthy people with short follow-up; says nothing about efficacy. Participant ages are not given in the abstract.

PubMed 34346165 DOI 10.1111/jcmm.16693

Preclinical (animal / cell)

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.

Bock-Marquette I, Saxena A, White MD, et al. · Nature · 2004

Design
Mouse coronary ligation model and cultured cardiac cells
Participants / model
Embryonic and postnatal mouse cardiomyocytes in culture; adult mice after coronary artery ligation
Sample size
not stated in the abstract
Principal findings
Tβ4 was reported to promote myocardial and endothelial cell migration and cardiomyocyte survival, to form a complex with PINCH and ILK activating Akt, and, after coronary ligation in mice, to upregulate ILK and Akt activity, enhance early myocyte survival and improve cardiac function.
Limitations
Mouse and cell-culture study; relevance to human heart disease is not established.

PubMed 15565145 DOI 10.1038/nature03000

Preclinical (animal / cell)

Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization.

Smart N, Risebro CA, Melville AA, et al. · Nature · 2007

Design
Mouse genetic and explant experiments
Participants / model
Mouse hearts and adult epicardial explants
Sample size
not stated in the abstract
Principal findings
Tβ4 was reported to be essential for coronary vessel development in mice and to stimulate outgrowth from quiescent adult epicardial explants with differentiation into fibroblasts, smooth muscle and endothelial cells; its cleavage product AcSDKP enhanced endothelial differentiation from adult epicardially derived cells.
Limitations
Developmental and explant experiments; the abstract does not report an adult in vivo repair outcome, and translation to people is unproven.

PubMed 17108969 DOI 10.1038/nature05383

Preclinical (animal / cell)

Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice.

Philp D, Badamchian M, Scheremeta B, et al. · Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2003

Design
Full-thickness dermal wound models in rats and mice
Participants / model
Normal rats, db/db diabetic mice and 26-month-old aged mice
Sample size
not stated in the abstract
Principal findings
Tβ4 (in saline or hydrogel) was reported to increase wound contracture and collagen deposition in diabetic mice, and to accelerate healing with increased keratinocyte migration in aged mice; a seven-amino-acid peptide from the actin-binding region gave comparable activity in aged animals.
Limitations
Animal skin-wound models; sample sizes are not given in the abstract and effects in chronic human wounds are not shown by this study.

PubMed 12581423 DOI 10.1046/j.1524-475x.2003.11105.x

Preclinical (animal / cell)

Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells.

Malinda KM, Goldstein AL, Kleinman HK · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 1997

Design
In vitro migration assays and an in vivo implanted-Matrigel assay
Participants / model
Human umbilical vein endothelial cells and subcutaneously implanted Matrigel
Sample size
not stated in the abstract
Principal findings
Tβ4 was reported to act as a chemoattractant for endothelial cells (four- to sixfold over medium alone in Boyden chambers), speed closure of a scratch-wounded monolayer, increase matrix metalloproteinase production and stimulate cell migration into implanted Matrigel.
Limitations
Cell-based and short-term assays; they model one step of angiogenesis and do not show new functional vessels or clinical benefit.

PubMed 9194528 DOI 10.1096/fasebj.11.6.9194528

Preclinical (animal / cell)

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.

Biçer O, Adanir O, Güleryüz Y, et al. · Joint diseases and related surgery · 2026

Design
Randomised four-group rat Achilles tendon transection-and-repair model, with four weeks of treatment
Participants / model
Male Sprague-Dawley rats given BPC-157, "synthetic thymosin beta-4 (TB-500)", both, or no treatment
Sample size
32 rats (8 per group)
Principal findings
The TB-500 group was reported to have higher maximum load to failure (statistically significant versus control) and lower Bonar and Movin histological scores; the combination did not add benefit over either agent alone.
Limitations
Small exploratory rat study at one time point; the abstract does not define the chemical identity of the TB-500 used, so applicability to full-length Tβ4 is unknown.

PubMed 42542926 DOI 10.52312/jdrs.2026.2951

Review

Thymosin β4 and Actin: Binding Modes, Biological Functions and Clinical Applications.

Ying Y, Lin C, Tao N, et al. · Current protein & peptide science · 2023

Design
Narrative review
Participants / model
Published mechanistic, preclinical and clinical literature on Tβ4
Sample size
not applicable (narrative review)
Principal findings
Summarises Tβ4 as a G-actin sequestering peptide that binds actin 1:1 and affects cell motility and differentiation, and reviews proposed roles in inflammation, angiogenesis, wound healing and organ protection.
Limitations
Narrative review without a stated systematic search, and much of the cited work is preclinical.

PubMed 36464872 DOI 10.2174/1389203724666221201093500

Review

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026

Design
Narrative review
Participants / model
Peptides marketed directly to patients, including Tβ4 (thymosin beta-4) and TB-500 (listed separately as a thymosin beta-4 fragment)
Sample size
not applicable (narrative review)
Principal findings
The abstract states that many unapproved peptides show favourable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce and there is potential for serious harm to patients.
Limitations
Narrative review focused on sports medicine; the abstract does not give compound-by-compound detail.

PubMed 41966639 DOI 10.1007/s40279-026-02437-0

Last reviewed: 20 November 2026